Dolutegravir and Empagliflozin Interaction

Understanding the Dolutegravir and Empagliflozin Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Dolutegravir belongs to the Integrase Strand Transfer Inhibitor class and Empagliflozin belongs to the SGLT2 Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Dolutegravir blocks the kidneys from removing metformin from the body. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Dolutegravir has 28 total documented interactions on file in this dataset, and Empagliflozin has 10. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to adjust your dose or monitor you more closely for side effects. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Dolutegravir or Empagliflozin based on a web page, speak with your prescriber or pharmacist before making any change.